TY - JOUR
T1 - Calcium-atpase activity in cystic fibrosis erythrocyte membranes
T2 - Decreased activity in patients with pancreatic insufficiency
AU - Dearborn, Dorr G.
AU - Wityk, Robert J.
AU - Johnson, Lynelle R.
AU - Poncz, Louis
AU - Stern, Robert C.
PY - 1984/9
Y1 - 1984/9
N2 - The activity of Ca-ATPase (Ca2+, Mg2+-ATPase, ATP phosphohydrolase, EC 3.6.1.3) was measured in erythrocyte membrane preparations from 37 cystic fibrosis patients, 27 with pancreatic insufficiency and 10 with pancreatic sufficiency, from 24 healthy controls. The mean maximal calcium-stimulated specific activities, in the absence and presence of purified calmodulin, of the pancreatic sufficient patients (34.3 ± 4.2 and 75.9 ± 6.9 nmol/min/mg) was indistinguishable from that of controls (35.8 ± 2.6 and 84.3 ± 4.7 nmol/min/mg), while both activities of patients with pancreatic insufficiency were significantly decreased (28.9 ± 1.3, p <0.02; 65.2 ± 3.0, p <0.001) compared to the control group. Similarly, the mean erythrocyte membrane (Na + K)ATPase activity was decreased only for those patients with a history of steatorrhea and who clinically required pancreatic enzyme therapy and had low immunoreactive trypsin levels (10.6 ± 0.8 versus control, 13.4 ± 1.1, and pancreatic sufficient patients, 13.3 ±1.4 nmol/min/mg; p <0.025). No correlation was found between any of the ATPase activities and the clinical scores of the patients, suggesting the lack of significant contribution of general clinical status to the activities of those cation transporters.
AB - The activity of Ca-ATPase (Ca2+, Mg2+-ATPase, ATP phosphohydrolase, EC 3.6.1.3) was measured in erythrocyte membrane preparations from 37 cystic fibrosis patients, 27 with pancreatic insufficiency and 10 with pancreatic sufficiency, from 24 healthy controls. The mean maximal calcium-stimulated specific activities, in the absence and presence of purified calmodulin, of the pancreatic sufficient patients (34.3 ± 4.2 and 75.9 ± 6.9 nmol/min/mg) was indistinguishable from that of controls (35.8 ± 2.6 and 84.3 ± 4.7 nmol/min/mg), while both activities of patients with pancreatic insufficiency were significantly decreased (28.9 ± 1.3, p <0.02; 65.2 ± 3.0, p <0.001) compared to the control group. Similarly, the mean erythrocyte membrane (Na + K)ATPase activity was decreased only for those patients with a history of steatorrhea and who clinically required pancreatic enzyme therapy and had low immunoreactive trypsin levels (10.6 ± 0.8 versus control, 13.4 ± 1.1, and pancreatic sufficient patients, 13.3 ±1.4 nmol/min/mg; p <0.025). No correlation was found between any of the ATPase activities and the clinical scores of the patients, suggesting the lack of significant contribution of general clinical status to the activities of those cation transporters.
UR - http://www.scopus.com/inward/record.url?scp=0021249182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021249182&partnerID=8YFLogxK
U2 - 10.1203/00006450-198409000-00018
DO - 10.1203/00006450-198409000-00018
M3 - Article
C2 - 6091022
AN - SCOPUS:0021249182
SN - 0031-3998
VL - 18
SP - 890
EP - 895
JO - Pediatric research
JF - Pediatric research
IS - 9
ER -